Long-term follow-up of patients with relapsed/refractory multiple myeloma after BCMA CAR-T-cell therapy
{{output}}
Background: B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy has demonstrated potent short-term efficacy in patients with relapsed/refractory multiple myeloma (R/R MM); however, long-term c... ...
